![1]()
News
Two swings, two misses with colchicine, Vascepa in COVID-19
September 1, 2021
The study cohorts varied from healthcare and public workers at high risk for infection to individuals already hospitalized with COVID-19.
![1]()
News
EMPEROR-Preserved spouts torrent of reports on empagliflozin treatment of HFpEF
August 31, 2021
The primary report from EMPEROR-Preserved on using empagliflozin to treat patients with HFpEF arrived with four other analyses published in its wake.
![1]()
News
Dapagliflozin in HFrEF may cut arrhythmias, sudden death: DAPA-HF
August 27, 2021
Response to the positive findings was tempered, however, by the post hoc nature of the analysis, choice of primary outcome, and inconsistencies between key subgroups.
![1]()
News
ICMs detect serious arrhythmias in high-risk post-MI patients: SMART-MI
August 27, 2021
In patients with modestly reduced left ventricular ejection fraction after MI, implantable monitors detect many times more arrhythmias than usual care, the SMART-MI trial showed.
![1]()
News
EMPEROR-Preserved: Empagliflozin scores HFpEF breakthrough
August 27, 2021
Empagliflozin is the first treatment to produce an unequivocal, hard-endpoint benefit in patients with heart failure with preserved ejection fraction, a practice-changing result.
![1]()
News
Move from awareness to action to combat racism in medicine
August 12, 2021
Calls to action to address structural racism include learning from policies, prioritizing voting, and educating children.
News
Febrile infant guideline allows wiggle room on hospital admission, testing
August 12, 2021
Evidence-based guidelines use language to guide, but not direct, clinicians in balancing the risks of infections and invasive procedures.
News
DOACs best aspirin after ventricular ablation: STROKE-VT
August 2, 2021
Cerebrovascular protection was far better on DOACs after catheter ablation for VT or extrasystoles in the trial and may yet be further improved.
![1]()
News
ESC heart failure guideline to integrate bounty of new meds
July 29, 2021
It has a simple answer to a seemingly complex issue: how to merge the newly approved with mainstay drug therapies. And it conditionally okays meds in a group long without guideline-directed options.
![1]()
News
C. Diff eradication not necessary for clinical cure of recurrent infections with fecal transplant
July 27, 2021
“I think the advice should be: Give a full anti–C. diff antibiotic course to treat the C. diff infection, and then give FMT afterward to restore the microbiota.”
